ArchiveAugust 2016

SurveySpeak & ClinicSpeak: lymphopaenia survey results

A lot of work needs to be done to activate MSers to become more engaged in their treatments. #MSBlog #SurveySpeak #ClinicSpeak “Many thanks to those of you who completed yesterday’s lymphopaenia survey. The results indicate that too few of you are engaged with your pharmacovigilance. You need to engage in tracking your own blood and urine results and understand why you are doing this...

Progressive MS deja vu

Last year we there was a buzz at ECTRIMS about ocrelizumab and this year it may well be Siponimod and its influence on secondary progressive MS. This is to be presented at the late breaking session at ECTRIMS 2016. Is this a game changer? The disruptor for MS pharma, is fingolimod coming-off patent in 2019. With the development of generics the price tumbles (except that MS pharma...

Siponimod saving nerves

Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L, Schubart A, Mandolesi G, Centonze D. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1):207. BACKGROUND:Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis...

ResearchSpeak: low lymphocyte counts in MSers

Do you have a normal lymphocyte count? Do you know your lymphocyte counts? #ResearchSpeak #MSBlog #MSResearch “The retrospective study below found that 1 in 10 DMT-naive MSers had low lymphocyte counts and in the majority of these no obvious cause could be found. The authors’ suggest the lymphopaenia is due to autoimmunity, or is stress-induced through increased cortisol production or...

Metabolic problems in immune cells can cause autoimmunity

Immunol Cell Biol. 2016 Aug 26. doi: 10.1038/icb.2016.77. [Epub ahead of print] “Immunometabolism and autoimmunity”. Freitag J, Berod L, Kamradt T, Sparwasser T. Abstract A continuous increase in the prevalence of autoimmune diseases is to be expected in the aging societies world-wide. Autoimmune disorders not only cause severe disability and chronic pain, but also lead to...

SurveySpeak: Impact, or lack of it

How do you feel about research, or academic, IMPACT? It is a sad fact of life in the modern university. #SurveySpeak #MSBlog  “One of our successes this year has been our medical school investing in Alison Thomson our designer; she has officially been appointed as a lecturer. This is the first time our University has embedded a designer within a biomedical research environment. As...

Safety of daclizumab: 3-year results from the SELECTED study

The paper: Gold, Ralf, et al. “Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.“ BMC Neurology 16.1 (2016): 1. Background: This paper reports early results from a clinical trial evaluating a new drug for relapsing-remitting Multiple Sclerosis (MS)1. The drug – daclizumab – is a...

Pregnancy and Natalizumab

Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M.Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.BMC Neurol. 2016 Aug 24;16(1):150. doi: 10.1186/s12883-016-0674-4. BACKGROUND: Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who...

Does the early bird get the worm in CIS? The 11 year follow-up to the BENEFIT study

The paper: Kappos, et al. “The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.“ Neurology (2016): 10-1212. Background: Multiple Sclerosis (MS) often starts as an individual episode of neurological dysfunction. At this early stage, termed a clinically isolated syndrome (CIS), it is often difficult to predict who will go on to develop...

Controlling flu like symptoms with interferons

Halper J, Centonze D, Newsome SD, Huang D, Robertson C, You X, Sabatella G, Evilevitch V, Leahy L. Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique. Int J MS Care. 2016; 18(4):211-8 BACKGROUND: Flu-like symptoms (FLSs) and injection-site reactions (ISRs) have been...

Translate

Categories

Recent Posts

Recent Comments

Archives